Anti-BAFFR antibody formulations and methods of use thereof
Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstitut...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Schaadt, Eveline Heusser, Christoph Neugebauer, Julia Woisetschlaeger, Maximilian Cosenza, Marta Urlinger, Stefanie |
| description | Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US10899841B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US10899841B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US10899841B23</originalsourceid><addsrcrecordid>eNrjZLB2zCvJ1HVydHMLUkgEMpPyUyoV0vKLcktzEksy8_OKgaIpCrmpJRn5KcUK-WkKpcWpCiUZqUWp-Wk8DKxpiTnFqbxQmptB0c01xNlDN7UgPz61uCAxOTUvtSQ-NNjQwMLS0sLE0MnImBg1AGG6LxM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anti-BAFFR antibody formulations and methods of use thereof</title><source>esp@cenet</source><creator>Schaadt, Eveline ; Heusser, Christoph ; Neugebauer, Julia ; Woisetschlaeger, Maximilian ; Cosenza, Marta ; Urlinger, Stefanie</creator><creatorcontrib>Schaadt, Eveline ; Heusser, Christoph ; Neugebauer, Julia ; Woisetschlaeger, Maximilian ; Cosenza, Marta ; Urlinger, Stefanie</creatorcontrib><description>Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210126&DB=EPODOC&CC=US&NR=10899841B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210126&DB=EPODOC&CC=US&NR=10899841B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Schaadt, Eveline</creatorcontrib><creatorcontrib>Heusser, Christoph</creatorcontrib><creatorcontrib>Neugebauer, Julia</creatorcontrib><creatorcontrib>Woisetschlaeger, Maximilian</creatorcontrib><creatorcontrib>Cosenza, Marta</creatorcontrib><creatorcontrib>Urlinger, Stefanie</creatorcontrib><title>Anti-BAFFR antibody formulations and methods of use thereof</title><description>Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB2zCvJ1HVydHMLUkgEMpPyUyoV0vKLcktzEksy8_OKgaIpCrmpJRn5KcUK-WkKpcWpCiUZqUWp-Wk8DKxpiTnFqbxQmptB0c01xNlDN7UgPz61uCAxOTUvtSQ-NNjQwMLS0sLE0MnImBg1AGG6LxM</recordid><startdate>20210126</startdate><enddate>20210126</enddate><creator>Schaadt, Eveline</creator><creator>Heusser, Christoph</creator><creator>Neugebauer, Julia</creator><creator>Woisetschlaeger, Maximilian</creator><creator>Cosenza, Marta</creator><creator>Urlinger, Stefanie</creator><scope>EVB</scope></search><sort><creationdate>20210126</creationdate><title>Anti-BAFFR antibody formulations and methods of use thereof</title><author>Schaadt, Eveline ; Heusser, Christoph ; Neugebauer, Julia ; Woisetschlaeger, Maximilian ; Cosenza, Marta ; Urlinger, Stefanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US10899841B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Schaadt, Eveline</creatorcontrib><creatorcontrib>Heusser, Christoph</creatorcontrib><creatorcontrib>Neugebauer, Julia</creatorcontrib><creatorcontrib>Woisetschlaeger, Maximilian</creatorcontrib><creatorcontrib>Cosenza, Marta</creatorcontrib><creatorcontrib>Urlinger, Stefanie</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Schaadt, Eveline</au><au>Heusser, Christoph</au><au>Neugebauer, Julia</au><au>Woisetschlaeger, Maximilian</au><au>Cosenza, Marta</au><au>Urlinger, Stefanie</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anti-BAFFR antibody formulations and methods of use thereof</title><date>2021-01-26</date><risdate>2021</risdate><abstract>Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US10899841B2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Anti-BAFFR antibody formulations and methods of use thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T15%3A29%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Schaadt,%20Eveline&rft.date=2021-01-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS10899841B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |